Loading clinical trials...
Loading clinical trials...
ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection: A Phase 2A Open-Label Segment Followed by a Phase 2B Double-Blind Vancomycin-Controlled Segment
Conditions
Interventions
Ibezapolstat
Vancomycin
Locations
29
United States
Acurx Site #118: Dr Janet Reiser
Scottsdale, Arizona, United States
Acurx Site #115: Dr Neera Grover
Apple Valley, California, United States
Acurx Site #125: Dr Karen Simon
Camarillo, California, United States
Acurx Site #111: Dr Jatinder Pruthi
Lancaster, California, United States
Acurx Site #131: Dr Michael Jardula
Palm Springs, California, United States
Acurx Site #129: Dr Stuart Cohen
Sacramento, California, United States
Start Date
March 6, 2020
Primary Completion Date
October 3, 2023
Completion Date
November 15, 2023
Last Updated
January 17, 2025
NCT06237452
NCT04014413
NCT04003818
NCT05826418
NCT04100603
NCT03350711
Lead Sponsor
Acurx Pharmaceuticals Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions